


Fourth Quarter 2022 Results Call Corporate Update & Financial Results

February 21, 2023



Forward-Looking Statements



BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertainties which may cause our actual results, performance or achievements to be materially different from any future results or performances expressed or implied in this presentation. You should not place undue reliance on the forward-looking statements. For additional information, including important risk factors, please refer to BioCryst’s documents filed with the SEC and located at <https://ir.biocryst.com/financial-information/sec-filings>.

Agenda

- ◆ Corporate Update:

Jon Stonehouse – President and Chief Executive Officer

- ◆ ORLADEYO[®] (berotralstat) Launch Update:

Charlie Gayer – Chief Commercial Officer

- ◆ Pipeline Update

Dr. Helen Thackray – Chief Research and Development Officer

- ◆ Financial Update

Anthony Doyle – Chief Financial Officer

- ◆ Summary and Q&A

Finance Summary

(figures in millions)

4Q22 Cash Position

Cash, cash equivalents, restricted cash & investments at December 31, 2021	\$518
Cash, cash equivalents, restricted cash & investments at December 31, 2022	\$444
Senior Credit Facility ^A	\$241

2023 FY Guidance

ORLADEYO Revenue	≥\$320
Operating Expenses (excluding non-cash comp)	\$375

A – From Athyrium Capital Management, term loans of \$200M interest-only for 5-year term, \$40.5 in interest payment-in-kind (PIK) has been added to principal since issuance

Fourth Quarter 2022 Results Call Corporate Update & Financial Results

February 21, 2023

